Trust Co. of Vermont Buys 574 Shares of AstraZeneca PLC (NASDAQ:AZN)

Trust Co. of Vermont raised its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 91.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,204 shares of the company’s stock after purchasing an additional 574 shares during the quarter. Trust Co. of Vermont’s holdings in AstraZeneca were worth $79,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in AZN. McClarren Financial Advisors Inc. raised its holdings in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca during the third quarter valued at approximately $28,000. Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca in the third quarter valued at $45,000. Hollencrest Capital Management lifted its position in AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares during the period. Finally, Versant Capital Management Inc boosted its stake in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after buying an additional 707 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $66.60 on Monday. The stock has a market capitalization of $206.50 billion, a price-to-earnings ratio of 31.87, a P/E/G ratio of 1.05 and a beta of 0.46. The firm’s 50-day moving average price is $66.11 and its two-hundred day moving average price is $74.48. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 EPS. On average, equities analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.